Literature DB >> 3168149

Disposition of ifosfamide in patients receiving ifosfamide infusion therapy for the treatment of cervical carcinoma.

R Pearcey1, R Calvert, A Mehta.   

Abstract

The disposition of ifosfamide was investigated in nine patients receiving a total of 23 72-h infusions. There was no linear relationship between steady-state plasma concentrations and either vomiting or CNS toxicity. The steady-state plasma concentrations were reproducible within patients, but there was a wide variation between patients. The progress of the disease did not affect the disposition of ifosfamide.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3168149     DOI： 10.1007/bf00254245

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  3 in total

1.  Encephalopathy associated with ifosphamide/mesna therapy.

Authors:  C A Meanwell; A E Blake; T N Latief; G Blackledge; J J Mould; D R Blake; I C Shaw; L Honigsberger; D Spooner; A C Williams
Journal:  Lancet       Date:  1985-02-16       Impact factor: 79.321

2.  Ifosfamide/mesa and encephalopathy.

Authors:  B M Cantwell; A L Harris
Journal:  Lancet       Date:  1985-03-30       Impact factor: 79.321

3.  Pharmacokinetics of intravenous cyclophosphamide in man, estimated by gas-liquid chromatography.

Authors:  F D Juma; H J Rogers; J R Trounce; I D Bradbrook
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333
  3 in total
  7 in total

1.  The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients.

Authors:  L D Lewis; D L Fitzgerald; P Mohan; N Thatcher; P G Harper; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

Review 2.  Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

Authors:  K L Dechant; R N Brogden; T Pilkington; D Faulds
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

4.  Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children.

Authors:  J Boos; U Welslau; J Ritter; G Blaschke; G Schellong
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 5.  Dosing and side-effects of ifosfamide plus mesna.

Authors:  W P Brade; K Herdrich; U Kachel-Fischer; C E Araujo
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 6.  Ifosfamide pharmacokinetics.

Authors:  L D Lewis
Journal:  Invest New Drugs       Date:  1991-11       Impact factor: 3.850

7.  Toxicity of ifosfamide, cyclophosphamide and their metabolites in renal tubular cells in culture.

Authors:  M Mohrmann; S Ansorge; U Schmich; B Schönfeld; M Brandis
Journal:  Pediatr Nephrol       Date:  1994-04       Impact factor: 3.714
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.